R

Roche

Global pharmaceuticals and diagnostics company

Head of Automation

Full-TimeUpdated on 10/23/2026
No salary listed
Expert
Bachelor's
Shanghai, China
In Person
Electrical EngineeringControls & Automation Engineering

About the job

Requirements
  • A bachelor's degree or above in Electrical Engineering, Automation, Mechanical Engineering, Biopharmaceutical Engineering, or a related field.
  • At least 15 years of automation system management experience in the injection pharmaceutical industry; multinational biopharma experience is preferred.
  • At least 5 years of people management experience.
  • Experience with strategic aseptic filling facility projects, including design, commissioning, and qualification.
  • Experience with new facility startup readiness and operation ramp-up, including organization, people, and operation management systems.
  • Strong knowledge of automation systems for drug product facilities.
  • Ability to think strategically, translate strategies into actionable plans, and apply agile ways of working.
  • Fluent English communication skills, including the ability to communicate and collaborate effectively with team members and stakeholders.
Responsibilities
  • Manage, maintain, and optimize site automation systems, including automated production equipment, control systems, related software applications, and computerized systems, to ensure efficient, controllable, and compliant production processes.
  • Support project and startup phases and liaise with engineering firms on the design, construction, and qualification of automation systems to ensure required standards and quality.
  • Lead the team in strategic project development in China and enable the team to deliver its objectives.
  • Support strategic project realization, including automation systems design, qualification, operational readiness, and startup for facilities, utilities, and equipment.
  • Build and maintain site automation systems, including specifying, sourcing, installing, and qualifying automation and controls equipment and systems such as Manufacturing Execution Systems, PI, Laboratory Information Management Systems, Environmental Monitoring Systems, Building Automation Systems, Supervisory Control and Data Acquisition, and Programmable Logic Controllers.
  • Train site users in system operation and provide shop-floor service during production.
  • Implement the site digital roadmap in accordance with Roche global strategy.
  • Apply leadership commitments, remove barriers, develop people's skills and technical capabilities, and foster an environment that enables strong performance.
  • Build and retain an inclusive workforce and foster an environment that values diversity of thought and perspective.
  • Build and maintain partnerships with site leaders to align on strategic projects and day-to-day activities.
  • Manage department daily Safety, Health, and Environment activities, implement site procedures and programs, achieve site and corporate Safety, Health, and Environment key performance indicators, and promote employee safety behavior.
  • Lead, coach, and guide the organization; manage team members' performance and development to achieve organizational goals and support their professional growth.
  • Build a talent pipeline and succession plans for key positions.
  • Promote continuous improvement, lean leadership, transparency, high performance, empowerment, and innovation.
  • Represent automation in project design, construction, and qualification, contributing to project delivery through specification, sourcing, installation, and qualification.
  • Establish and develop site automation and control systems in line with Roche standards.
  • Assist the Engineering Head in establishing the team and hiring schedule to meet project and production ramp-up plans.
  • Develop team capability through coaching, mentoring, training, competency development, and appraisal programs.
  • Support implementation activities and improve the management of and access to business-critical scientific data across scientific disciplines.
  • Consult on automation systems, computerized systems, and software implementation and validation.
  • Perform work safely and meet required training requirements.
  • Provide workable software and systems solutions aligned with site digital strategy.
  • Understand Automation/IT and business initiatives, strategies, and future needs, and align Automation/OT strategy accordingly.
  • Monitor emerging technologies that could benefit the site and promote relevant opportunities internally.
  • Set strategic direction for the automation group, particularly for software and hardware, and implement the site digital roadmap in line with Roche global strategy.
  • Provide subject-matter-expert support to manufacturing and other departments on process automation equipment design and operation.
  • Troubleshoot and conduct technical analyses of manufacturing equipment and process automation systems, including PI data analysis and code review and troubleshooting.
  • Act as controls engineering lead for technology transfer or new processes introduced into facilities.
  • Support production and project teams with automation and controls questions.
  • Develop technical knowledge of manufacturing equipment and process automation systems.
  • Ensure activities are executed professionally and economically and maintain high availability of manufacturing units and equipment.
  • Train site users in system operation and provide shop-floor service during production.
  • Create, revise, and review automation- and manufacturing-related standard operating procedures, functional specifications, work instructions, and equipment and process changes.
  • Administer automation systems at a high level, including management of user roles, configurations, security rights, and access rights.
Desired Qualifications
  • Multinational biopharma experience.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Performance Bonus

Company News

Yahoo Finance
Oct 22nd, 2026
Roche reaffirms outlook as Q3 sales rise 7% to $19.6B, but growth doubts linger

Roche reaffirmed its 2025 outlook on Thursday and beat third-quarter sales expectations, but questions about its long-term growth remain. Group sales rose 7% to 16.1 billion Swiss francs (about $19.6 billion), ahead of the 15.8 billion franc consensus estimate. Jefferies analyst Michael Leuchten said a new resource planning system boosted revenue, making the results "cosmetically ahead." Roche still expects group sales growth in the "mid single digit range" and did not raise guidance. Sales of allergy and asthma drug Xolair reached only 848 million francs, well below estimates. A copycat version launched in the US this month, and Ocrevus and Tecentriq face generic competition by 2030. Roche is counting on its breast cancer pill giredestrant, which awaits a US Food and Drug Administration decision by December 18, and on obesity drugs. It says the products could together reach $9 billion in peak annual sales.

CNBC
Oct 22nd, 2026
Roche CEO presses Germany on growth strategy as drugmaker pauses investment there

Roche chief executive officer Thomas Schinecker has challenged Germany over its growth strategy, saying pharmaceutical firms are "the industry they need to bet on." Schinecker discussed the company's third-quarter earnings and its recent expansion in China. He also outlined recent pharmaceutical developments at the business. He explained why Roche has paused investment in Germany.

Yahoo Finance
Oct 16th, 2026
FDA approves Roche's Enspryng as first at-home injection for thyroid eye disease

Roche said the US Food and Drug Administration (FDA) has approved Enspryng (satralizumab) for adults with thyroid eye disease (TED). It is the first and only at-home subcutaneous treatment for the condition, and a patient or caregiver can administer it after training. In the Phase III SatraGO-2 trial, 52.9% of active TED patients on Enspryng had a proptosis (eye bulging) response, against 23.4% on placebo. Double vision fell in 60.7% of patients, against 25.8%. The SatraGO-1 trial missed its primary endpoint at Week 24. No new safety signals emerged. TED affects about 155 in every 100,000 people in the US. This is Enspryng's second approval, after neuromyelitis optica spectrum disorder in 2020. The FDA is also reviewing it for myelin oligodendrocyte glycoprotein antibody-associated disease, with a decision expected in January 2027.

Yahoo Finance
Oct 9th, 2026
FDA approves Roche's Tecentriq for stage III colon cancer, cutting recurrence risk by 50%

The US Food and Drug Administration has approved Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III deficient DNA mismatch repair colon cancer. This marks Tecentriq's twelfth approved indication in the US. The approval follows the phase III ATOMIC study, published in The New England Journal of Medicine, which demonstrated that Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival rate was 86% with the combination versus 76% with chemotherapy alone. Nearly 25% of colon cancers are diagnosed at stage III, and almost one in three stage III patients experience recurrence within five years. This represents the first approved adjuvant immunotherapy regimen for this patient population. Roche is pursuing further regulatory filings, including with the European Medicines Agency.

Yahoo Finance
Sep 30th, 2026
Roche's enicepatide shows 22.5% weight loss in 48 weeks, challenging Eli Lilly and Novo Nordisk

Roche posted strong Phase 2 results for its weight loss drug enicepatide, showing 22.5% mean weight loss over 48 weeks. This compares favourably to Eli Lilly's Zepbound, which achieved 20.2% weight loss over 72 weeks in a separate trial. In another Phase 2 study, enicepatide demonstrated HbA1c reductions of up to 2.65 percentage points in diabetic patients after 48 weeks, compared to tirzepatide's 2.37 percentage points after 52 weeks. Despite promising results, Roche faces stiff competition from Novo Nordisk and Eli Lilly, which both have deep pipelines in development. Novo Nordisk's CagriSema is nearing approval, whilst Eli Lilly's retatrutide has posted strong Phase 3 results. Roche's revenue grew 6% year over year in the first half of the year to 30.4 billion Swiss francs.